Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human

British Journal of Clinical Pharmacology

Volumn 54, Issue 3, 2002, Pages 246-250

  Zhang, Mei ^a   Fawcett, J Paul ^b   Shaw, John P ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Formoterol enantiomers; Stereoselective glucuronidation; Urinary excretion

Indexed keywords

BETA GLUCURONIDASE; FORMOTEROL FUMARATE; GLUCURONIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; ENANTIOMER; FEMALE; GENDER; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; SEX DIFFERENCE; STATISTICAL ANALYSIS; STEREOCHEMISTRY; URINALYSIS; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETHANOLAMINES; FEMALE; GLUCURONIDES; HUMANS; MALE; MIDDLE AGED; SEX CHARACTERISTICS; STEREOISOMERISM;

EID: 0036378220     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01641.x     Document Type: Article

References (12)

1. Faulds D, Hollingshead LM, Goa KL. Formoterol. Drugs 1991; 42: 115-117.
2. Trofast J, Osterberg K, Kallstrom BL, Waldeck B. Steric aspects of agonism and antagonism at β-adrenoceptors: Synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers. Chirality 1991; 3: 443-450.
3. Kamimura H, Sasaki H, Higuchi S, Shiobara Y. Quantitative determination of the β-adrenoceptor stimulant formoterol in urine by gas chromatography mass spectrometry. J Chromatogr 1982; 229: 337-345.
4. Bindschedler M, Kaiser G, Preiswerk G, Patalano F. Biochemical and cardiovascular effects and urinary excretion of formoterol in healthy subjects after single inhaled doses. Am J Respir Crit Care Med 1997; 155 (4 part 2): A345.
5. 3H]formoterol in healthy men after combined i.v. & oral administration-mimicking inhalation. Drug Metab Dispos 1999; 27: 1104-1116.
6. Zhang M, Fawcett JP, Kennedy JM, Shaw JP. Stereoselective glucuronidation of formoterol by human liver microsomes. Br J Clin Pharmacol 2000; 49: 152-157.
7. Campestrini J, Lecaillon JB, Godbillon J. Automated and sensitive method for the determination of formoterol in human plasma by high-performance liquid chromatography and electrochemical detection. J Chromatogr B 1997; 704: 221-229.
8. Van den Berg BTJ, Braat MCP, van Boxtel CJ. Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing. Eur J Clin Pharmacol 1998; 54: 463-468.
9. Butter JJ, van den Berg BTJ, Portier EJG, Kaiser G, van Boxtel CJ. Determination by HPLC with electrochemical detection of formoterol enantiomers in urine of healthy human subjects after single dose racemate inhalations. Pharm World Sci 1995; 17(Suppl): D6.
10. Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della Cioppa G. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via aerolizer™. Eur J Clin Pharmacol 1999; 55: 131-138.
11. Butter JJ, van den Berg BTJ, Portier EJG, Kaiser G, van Boxtel CJ. Determination by HPLC with electrochemical detection of formoterol RR and SS enantiomers in urine. J Liquid Chromatogr Rel Tech 1996; 19: 993-1005.
12. Menzel S, Beck WS, Brune K, Geisslinger G. Stereoselectivity of biliary excretion of 2-arylpropionates in rats. Chirality 1993; 5: 422-427.